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Tbjective: This study was conducted to compare the composites of valve-related
omplications, namely reoperation, morbidity (defined as permanent neurologic or
ther functional impairment), and mortality, between bioprostheses and mechanical
rostheses for aortic valve replacement.
ethods: Between 1982 and 1998, 2195 bioprostheses were implanted in 2179 patients
nd 980 mechanical prostheses were implanted in 883 patients. Total follow-up was
6,442 years and 5740 years for bioprostheses and mechanical prostheses, respec-
ively. Eight variables were considered as predictors of risk for the composites of
alve-related complications.
esults: Linearized rates for valve-related reoperation were 1.3%/patient-year and
.3%/patient-year for bioprostheses and mechanical prostheses (P  .001), respec-
ively. All age groups were differentiated, except 70 years. Valve-related mor-
idity was differentiated for all age groups and overall, for bioprostheses and
echanical protheses, was 0.4 %/patient-year and 2.1%/patient-year, respectively
P  .001). Overall valve-related mortality was 1.0%/patient-year for bioprostheses
nd 0.7%/patient-year for mechanical prostheses (P  .018). Age and valve-type
ere predictive risk factors for reoperation and morbidity, whereas age alone was
redictive of mortality. Actual freedom from valve-related reoperation favored
echanical prostheses for all age groups, except 61-70 years and70 years. Actual
reedom from valve-related morbidity favored bioprostheses in all age groups,
xcept40 years. Actual freedom from valve-related mortality was undifferentiated
n patients 51-60, 61-70, and 70 years.
onclusion: No differences were observed in valve-related reoperation and mortal-
ty in patients 60 years. Comparative evaluation gives high priority for biopros-
heses in patients 60 years based on improved morbidity profile. This evaluation
xtends this center’s recommendation for bioprostheses in aortic valve replacement
o include patients 60 years.
 
he long-term performance of bioprostheses and mechanical prostheses
aortic and mitral valve replacement has been evaluated by two large ran-
domized control studies.1-4 These studies evaluated survival and valv
elated complications. Little is known regarding the performance of biologic and
echanical valves in terms of composites of complications, namely valve-related
eoperation, valve-related morbidity, and valve-related mortality, which are impor-
ant to the patient. Only one study in the literature thus far has used actual and
ctuarial methods to evaluate composites of valve-related complications in biopros-
heses and mechanical prostheses. Jamieson and colleagues5 recently published thei
esults concerning mitral valve replacement. This study will evaluate valve-related
he Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 6 1267
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A
CDeoperation, valve-related morbidity (defined as permanent
eurologic or other functional impairment), and valve-related
ortality for aortic valve replacement.
ethods
etween 1982 and 1998, a total of 2195 bioprostheses were
mplanted in 2179 patients and a total of 980 mechanical prosthe-
es were implanted in 883 patients. Patients considered for this
tudy had not undergone previous cardiac surgery procedures.
umulative follow-ups for the bioprosthesis (BP) and mechanical
rosthesis (MP) groups were 16,442.1 years and 5740.3 years,
espectively. Average follow-ups in years for the BP and MP
roups were 7.5%  4.7% and 5.9%  3.3% (P  .001), respec-
ively. Concomitant coronary revascularization was performed in
3.5% of the initial operations of BP patients and 26.0% of MP
atients. The male/female proportions for the BP and MP groups
ere 64.5:35.5 and 70.2:29.8, respectively. Mean patient age was
reater in the biological group than in the mechanical group (BP
9.7%  10.6% vs MP 58.2%  12.4%, P  .001).
During the 16-year period of this study, the following biopros-
heses were used: Carpentier-Edwards SAV (Edwards Lifesciences,
rvine, Calif; n  1728), Carpentier-Edwards Pericardial (n 
99), Medtronic Mosaic (Medtronic, Inc, Minneapolis, Minn; n 
64), and other (n  4). The mechanical prostheses used during
he study period were St Jude Medical (St Jude Medical Inc,
inneapolis, Minn; n  514), CarboMedics (Sorin CarboMedics
nc, Austin, Tex, n  463), and other (n  3).
ollow-up Procedure
he patients in this study were followed up regularly through the
niversity of British Columbia Cardiac Valve Database, with the
losing interval in the year 2000-2001. Information was received
hrough direct telephone interviews with patients and through
eview of medical records, including operative and consultation re-
orts. Vital statistics death registry was also used to ensure com-
leteness of mortality data.
tudy End Points
he three study end points were valve-related mortality, valve-
elated morbidity, and valve-related reoperation. These compos-
tes of complications, including valve-related complications, were
efined according to the “Guidelines for Reporting Morbidity and
ortality After Cardiac Valvular Operations.”6 Valve-related mor-
ality included death caused by structural valve deterioration, non-
tructural dysfunction, thrombosis, thromboembolism, hemorrhage,
r prosthetic valve endocarditis, and death related to reoperation
or a valve-related complication. Valve-related mortality included
udden unexplained, unexpected deaths. Valve-related reoperation
as reoperation for any valve-related complication. Valve-related
orbidity was defined in this study as permanent valve-related
Abbreviations and Acronyms
BP group  bioprosthesis group
MP groupmechanical prosthesis groupmpairment as a result of permanent neurologic or other functional c
268 The Journal of Thoracic and Cardiovascular Surgery ● Juneficit caused by structural valve deterioration, nonstructural dys-
unction, valve thrombosis, thromboembolism, hemorrhage, pros-
hetic valve endocarditis, or reoperation.
When a patient with a bioprosthetic valve underwent reopera-
ion with a mechanical prosthesis, or vice versa, the patient was
ensored from the former group after 30 days and entered in the
atter group. If the valve type did not change, the patient was kept
n his or her original group. Operative mortality (30-day mortality)
as attributed to the explanted valve and was subsequently used to
alculate valve-related mortality. Patient survival was therefore not
etermined in this study, because a small portion of the patients
ere included in both study arms. Variables considered as predic-
ors of risk for the composites of valve-related complications were
rosthesis type, age (continuous and categorical variables), gender,
rostheses size, and concomitant coronary revascularization. All
atients undergoing initial cardiac operations between 1982 and
998, as well as reoperation in 1999 to 2001, were included in this
nalysis.
tatistical Analysis
he baseline characteristics of the BP and MP groups were as-
essed by t tests for continuous variables and 2 for categorical
ariables. The freedom from the composites of valve-related com-
lications, namely valve-related morbidity, valve-related mortal-
ty, and valve-related reoperation, was calculated by Kaplan-Meier
ctuarial methods and compared with the log-rank statistic. The
ctual freedom or cumulative incidence was determined by the
odified Kaplan-Meier method described by Grunkemeier and
olleagues.7-10 Composites of valve-related complications we
lso described with the use of linearized rates, which describe the
umber of events per 100 patient-years or percent per patient-year.
omparisons between linearized rates were made with the log-
ikelihood ratio. Linearized occurrence rates are not recommended
or evaluation of structural valve deterioration and reoperation
esulting from structural valve deterioration owing to an acceler-
ting, rather than constant, hazard with time. The Weibull distri-
ution curve is the appropriate statistic to describe structural valve
eterioration and reoperation secondary to reoperation.7 Linear-
zed rates were used to describe valve-related reoperation as it was
nclusive of reoperation secondary to all causes, namely prosthetic
alve endocarditis, nonstructural dysfunction, and prosthesis throm-
osis in addition to structural valve deterioration. Predictors of risk
f the composites of complications were determined by univariate
nd multivariate Cox hazard analysis.
esults
he linearized occurrence rates of the composites of valve-
elated complications are described in Table 1. Ove
alve-related reoperation occurred at a rate of 1.3 events/
00 patient-years and 0.3 events/100 patient-years for pa-
ients receiving bioprostheses (BP group) and mechanical
rostheses (MP group), respectively (P .001). The BP and
P groups were also differentiated for all age groups,
xcept 70 years. In contrast to valve-related reoperation,
verall valve-related morbidity favored the BP versus the
P group (P  .001). This was also significant for all ageategories. Overall valve-related mortality for the BP and
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A
CDP groups were 1.0 events/100 patient-years and 0.7 events/
00 patient-years, respectively (P  .018).
Predictors of risk for composites of valve-related com-
lications are described in Table 2. Age and valve type
redictive of valve-related reoperation and morbidity,
hereas age alone was predictive of valve-related mortality.
The freedom (SD) from composites of valve-related
omplications are detailed for actual and actuarial freedom
o 15 years from valve-related reoperation, valve-related mor-
idity, and valve-related mortality in Figures 1 throug
or age groups 51-60 years, 61-70 years, and 70 years.
he actual freedom from valve-related reoperation in pa-
ients 51-60 years were 98.3%  0.9% and 59.7%  3.7%
or the MP and BP groups, respectively (actuarial freedom,
8.1%  1.0% for MP and 45.2%  4.9% for BP, P 
001) (Figure 1). Fifteen-year actual freedom from reop-
ration in the 61-70–year age group was 89.4%  8.7% for
he MP group and 87.9% 1.8% for the BP group, whereas
ctual freedom in the 70-year age group was 100 at 12
ears for the MP group and 97.4%  0.7% at 15 years for
he BP group (Figures 2 and 3). Figures 2 and 3 also sh
hat no significant difference was observed between the two
alve groups in the 61-70 –year age group and the 70-
ear age group by actuarial analysis.
The actual freedom from valve-related morbidity in pa-
ients 51-60, 61-70, and 70 years is described in Figure
o 6. Actual freedom from valve-related morbidity in
ients 51-60 years was 97.8%  1.0% for the BP group and
6.4%  2.3% for the MP group (actuarial 85.4%  2.5%
ABLE 1. Linearized occurrence rates of composites of va
Age groups
VR reop (% censored) VR
BP (%/pt-y) MP (%/pt-y) P value BP (%/pt-y
40 5.5 0.3 .001 0.0
1-50 4.3 0.6 .001 0.0
1-60 3.5 0.2 .001 0.3
1-70 1.0 0.3 .001 0.4
70 0.2 0.0 .091 0.5
otal 1.3 0.3 .001 0.4
R, Valve- related; BP, bioprosthesis group; MP, mechanical prosthesis g
ABLE 2. Predictive risk factors for composites of valve-r
Reoperation
HR* P value
ge 0.95 (0.94-0.96) .001
ender 1.04 (0.75-1.44) .812
alve type 0.22 (0.13-0.38) .001
ize 1.04 (0.98-1.10) .142
oncomitant CABG 0.87 (0.63-1.20) .390
aseline assumptions for dichotomous variables: gender, valve type, biop
The 95% confidence intervals for the hazard ratio are given in parentheses.
The Journal of Thoracice
 o r M P and 97.6%  1.1% for BP, P  .001) (Figure 4)
ctual freedom from morbidity also favored bioprostheses
n the 61-70–year age group and the 70-year age group
Figures 5 and 6). Actual freedom for patients 61-70 years
n the MP group was 84.4%  2.8% at 15 years and 96.6%
 0.8% at 15 years for those in the BP group (Figu
ctual freedom from morbidity in patients 70 years was
6.9%  3.4% for the MP group at 12 years and 95.9% 
.8% for the BP group at 15 years (Figure 6).
Freedom from valve-related mortality for patients 51-60
ears of age is described in Figure 7. Actual freedo
5 years for the MP and BP groups were 94.9% 2.2% and
3.2%  1.9%, respectively. Figure 7 also shows that
ifference was observed between either valve type based on
ctuarial analysis. Figure 8 describes the freedom from valve-
elated mortality for patients 61-70 years. Fifteen-year ac-
ual freedom was 91.1%  2.4% for the MP group and
8.3%  1.7% for the BP group. Figure 9 shows tha
5-year actual freedom from valve-related mortality in pa-
ients 70 years was 96.0%  2.0% at 12 years for the MP
roup and 87.9%  1.3% at 15 years for the BP group. No
ifference in valve-related mortality was observed be-
ween valve types (Figures 8 and 9).
In total, this study describes 3175 cardiac valve replace-
ents that were conducted on 3062 patients. There were
34 valve-related operations: 218 reoperations in the BP
roup and 16 in the MP group. The distributions by cause of
rst events for the BP group were nonstructural dysfunction,
0; prosthetic valve endocarditis, 28; structural valve dete-
elated complications by age group
idity (% censored) VR mortality (% censored)
MP (%/pt-y) P value BP (%/pt-y) MP (%/pt-y) P value
0.8 .011 1.1 0.0 .003
1.3 .001 0.8 0.5 .516
2.2 .001 0.6 0.5 .646
2.7 .001 1.0 1.1 .738
2.9 .001 1.3 1.1 .712
2.1 .001 1.0 0.7 .018
pt-y, patient-year.
d complications
Morbidity Mortality
HR* P value HR* P value
(1.01-1.05) .001 1.04 (1.03-1.06) .001
(0.80-1.70) .438 0.91 (0.65-1.29) .607
(4.58-9.44) .001 1.00 (0.68-1.48) .992
(0.98-1.14) .151 1.01 (0.95-1.08) .750
(0.80-1.50) .727 1.13 (0.85-1.51) .398
ses; concomitant coronary artery bypass graft (CABG). HR, Hazard ratio.lve-r
morb
)elate
1.03
1.17
6.57
1.06
1.06
rostheand Cardiovascular Surgery ● Volume 131, Number 6 1269
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CDioration, 145; and thrombosis, 5. In the MP group, the
istributions of first events were nonstructural dysfunction,
; prosthetic valve endocarditis, 6; and thrombosis, 1.
There were 211 valve-related deaths in this study, 171 of
hich were observed in the BP group. Hemorrhage was
escribed in 42 of these deaths: BP 27 and MP 15. In
atients 70 years, 17 bleeding events occurred in the BP
roup whereas none were observed in the MP group. In
atients 61-70 years, 7 bleeding events occurred in the BP
roup and 11 events occurred in the MP group. The distri-
ution of first events also included nonstructural dysfunc-
ion (BP 3; MP 1), prosthetic valve endocarditis (BP 28; MP
), structural valve deterioration (BP 29; MP 3), sudden
nexpected death (BP 15; MP 7), and thromboembolism
BP 69; MP 12).
iscussion
here is little documentation comparing the long-term per-
ormances of bioprostheses versus mechanical prostheses to
5 years. Further, the literature comparing biologic and
echanical valves has largely focused on individual valve-
elated complications. There has been little documentation
f composites of valve-related complications that are also
linically relevant. This study tracked the performance of
igure 2. Freedom from valve-related reoperation in patients
1-70 years. BP, Bioprosthesis group; MP, mechanical prosthesis
igure 1. Freedom from valve-related reoperation in patients
1-60 years. BP, Bioprosthesis group; MP, mechanical prosthesis
roup.roup. y
270 The Journal of Thoracic and Cardiovascular Surgery ● Juniologic and mechanical valves for use in aortic valve
eplacement to 15 years.
To summarize, this study found that linearized occur-
ence rates for valve-related reoperation favored mechanical
alves, except in patients 70 years. Valve-related morbid-
ty, defined as permanent neurologic or other functional
mpairment, favored bioprostheses for all age categories and
verall valve-related mortality favored mechanical prosthe-
es. Actual/actuarial freedom from these composites of
alve-related complications revealed results similar to the
inearized rates. Freedom from valve-related reoperation
avored mechanical valves for all age groups to 15 years,
xcept 61-70 years and 70 years. Fifteen-year freedom
rom valve-related morbidity favored biologic valves for all
ge groups, except in patients40 years of age at operation.
reedom from valve-related mortality was undifferentiated
etween valve types to 15 years for patients 51-60, 61-70,
nd70 years. Age and valve type were found to be predictive
isk factors for valve-related reoperation and morbidity,
hereas age alone was predictive of valve-related mortality.
The interpretation of these results is that biologic valves
ppear to be favorable in patients on the basis of the lower
ncidence of valve-related morbidity. Of course, biologic
alves were associated with increased overall valve-related
eoperation. Since no significant difference in reoperation
as observed between the MP and BP groups in patients
igure 3. Freedom from valve-related reoperation in patients>70
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.
igure 4. Freedom from valve-related morbidity in patients 51-60
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.
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A
CD1-70 years, biologic valves appear the clear preference for
atients in this age group; they offer an improved morbidity
rofile while not sacrificing durability. Valve-related mor-
ality was also undifferentiated between valve types in pa-
ients 61-70 years. In the 51-60–year age group, reoperation
avored mechanical prostheses, yet no difference in valve-
elated mortality was observed between valve types. This is
n important finding because patients in the sixth decade
eceiving biologic valves that are prone to valve-related
eoperation did not have any increased risk of dying from
hat reoperation. In fact, patients receiving bioprostheses
enefited from fewer valve-related morbid events that were
efined as permanent neurologic or other functional impair-
ent in this study.
The findings of this study are also consistent with work
onducted by other researchers. There have been two large
andomized trials to date comparing biologic and mechan-
cal heart valves. Hammermeister and colleagues’1,2 United
tates Veterans Affairs Study reported on 575 patients
ndergoing isolated aortic valve replacement or mitral valve
eplacement at 13 Veterans Affairs medical centers. Sur-
ival analysis at 15 years showed that all-cause mortality
as lower with mechanical prostheses in the context of
ortic valve replacement, but not mitral valve replacement.
iologic valves, whether implanted in the aortic or mitral
osition, were associated with significantly lower bleeding
igure 5. Freedom from valve-related morbidity in patients 61-70
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.
igure 6. Freedom from valve-related morbidity in patients >70
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group. y
The Journal of Thoracicates, but also more frequent cases of structural valve dete-
ioration. The Edinburgh Trial3,4 evaluated over 530 pa-
ients receiving either a Björk-Shiley tilting disc valve or a
orcine bioprosthesis. This study concluded that mechanical
rostheses had improved survival over bioprostheses at 12
ears, but not at 20 years after cardiac valve replacement.
his was true for both aortic and mitral valve replacement.
echanical prostheses were also found to be associated
ith a higher bleeding rate for both aortic and mitral valve
eplacement. Beyond these randomized trials, the consensus
n the literature is that biologic valves tend to be associated
ith increased structural valve deterioration and reopera-
ion, but lower bleeding and thromboembolic rates.11-13
Prasongsukarn, Jamieson, and Lichtenstein14 recently
ompared mechanical and bioprosthetic valves in patients
1-70 years in terms of combined major thromboembolism
nd hemorrhage and valve-related reoperation. That study
evealed no difference between biologic and mechanical
alves in terms of valve-related reoperation and mortality.
he 15-year actuarial freedom from reoperation of 85.8 for
ioprostheses and 82.2 for mechanical prostheses were
omparable with freedoms from reoperation of 77.5% 
.7% and 82.3%  15.0% for the BP and MP groups,
espectively, in this study. Further, similar to this study,
alve-related morbidity was significantly different between
iologic and mechanical groups. Fifteen-year actuarial free-
igure 7. Freedom from valve-related mortality in patients 51-60
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.
igure 8. Freedom from valve-related mortality in patients 61-70
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.
and Cardiovascular Surgery ● Volume 131, Number 6 1271
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CDom from valve-related morbidity of 95.4% and 79.9% for
ioprosthesis and mechanical prosthesis groups were also
omparable with freedoms of 95.6%  1.1% and 81.5% 
.7% in this study.
Jamieson’s group has also provided extensive documen-
ation in regard to the indications for implantation of bio-
rostheses and mechanical prostheses. In separate studies,
yers and colleagues15 have noted that patients with b-
rostheses were more likely to require valve-related reop-
ration than were those with mechanical prostheses. But
ortality from reoperation secondary to bioprosthetic aortic
tructural failure can be lowered by reoperation in patients
ith low, rather than medium to high, New York Heart
ssociation functional class.16 The relevance of these o-
ervations to this study is that patients with biologic valves
ay have an increased risk of reoperation, but may not
ecessarily have any increased risk of mortality from that
eoperation if closely monitored through a vigilant surveil-
ance program. Concomitant revascularization procedures
egatively influence survival in patients undergoing cardiac
alve replacement.17,18 However, Jamieson’s group19 has
ound that this is actually protective against structural valve
eterioration since patients are more likely to die than to
ave structural failure. This study considered all causes
eading to reoperation rather than simply reoperation result-
ng from structural valve deterioration alone.
Most recently, Jamieson and colleagues5 compared com-
osites of valve-related complications in biologic and me-
hanical heart valves in terms of mitral valve replacement.
n that report, 15-year freedom from valve-related reopera-
ion differentiated bioprostheses and mechanical prostheses
n patients 61-70 years, but not 70 years. Further, no
ifference was observed between valve types in terms of
5-year freedom from valve-related morbidity, whereas
reedom from valve-related mortality was differentiated in
atients 61-70 years. When compared with this study, clear
ifferences exist in the rationale for biologic and mechani-
al valves in the setting of aortic and mitral replacement
igure 9. Freedom from valve-related mortality in patients >70
ears. BP, Bioprosthesis group; MP, mechanical prosthesis group.eyond age alone. In the case of mitral replacement, mor-
272 The Journal of Thoracic and Cardiovascular Surgery ● Junidity was undifferentiated; thus reoperation and mortality
ere the major influences in determining 70 years as the
ecommended age. In the case of aortic valve replacement,
o differences were observed in terms of mortality in pa-
ients 61-70 years whereas differences were observed in the
orbidity profile; therefore morbidity was the most influ-
ntial variable.
The main limitation of this study was that patient sur-
ival for the BP and MP groups was not calculated. The
esign of this study was such that patients undergoing
eoperation with a different prosthesis were censored from
he former group and entered into the latter group after 31
ays. This precluded the calculation of survival because
atients were included into both study arms. Further, the
ean follow-up period for patients undergoing aortic valve
eplacement with a biologic valve was 7.5 years. Although
his ranks among the longest series reported in the literature,
ome instances of structural valve deterioration may be
issed, which may affect the incidence of reoperation and
alve-related mortality.
Notwithstanding, this study compares the performance
f biologic and mechanical valves to 15 years in terms of
omposites of valve-related complications. Biologic valves
re favorable in patients in their seventh decade because
hey provide a superior morbidity profile, defined as perma-
ent neurologic or other functional impairment, relative to
echanical valves. For the same age group, bioprostheses
ere undifferentiated in terms of valve-related reoperation
nd mortality, meaning that no compromise in durability or
urvival was observed with bioprostheses. Survival from
eoperation can also be improved through early re-referral
or operation when patients are in New York Heart Asso-
iation class I/II. These findings not only affirm this center’s
revious recommendation for biologic valves for aortic
alve replacement19-21 but extends this recommendation 
ossibly include patients 60 years of age.
We appreciate the help of Kevin Shillitto, who was involved in
he word processing of this manuscript.
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